Skip to main content
European Commission logo
español español
CORDIS - Resultados de investigaciones de la UE
CORDIS
CORDIS Web 30th anniversary CORDIS Web 30th anniversary

European Clinical Research Alliance on Infectious Diseases

Descripción del proyecto

Una red paneuropea contra las enfermedades infecciosas

El proyecto ECRAID-Base, financiado con fondos europeos, tiene como objetivo generar pruebas concretas para mejorar la prevención, el diagnóstico y el tratamiento de enfermedades infecciosas y responder mejor a las amenazas de las enfermedades infecciosas emergentes. El proyecto creará una red de investigación clínica paneuropea para reforzar la eficacia de las pruebas y desarrollar nuevas estrategias terapéuticas, preventivas o diagnósticas y mejorar la respuesta a nuevas amenazas para la salud pública. Esta red ya se ha empleado con éxito durante la pandemia de COVID-19, y se han aprendido algunas lecciones valiosas.

Objetivo

ECRAID-Base (European Clinical Research Alliance for Infectious Diseases) continues the activities of PREPARE, COMBACTE and ECRAID-Plan, which will lead to establishing ECRAID as an independent non-for-profit legal entity in December 2020. ECRAID-Base is the initial set of activities for ECRAID.
As a European clinical research network ECRAID-Base will generate rigorous evidence to improve diagnosis, prevention and treatment of infections and to better respond to EID threats.. The network has already been successfully used during the COVID-19 pandemic, with valuable lessons learned.
At the heart of ECRAID-Base are 6 perpetual studies; 5 observational studies in ICU (WP2), ER (WP3,4&5) and primary care (WP6), addressing infections relevant for AMR (VAP in WP2 & cUTI in WP3) and EID (ARI in WP4 & WP6, and Disease X in WP5). All will mature towards adaptive platform trials, with capability to rapidly respond to public health threats. These 5 studies will enroll around 20,000 patients per year.
The sixth perpetual study is the Randomized Embedded Multifactorial Adaptive Platform (REMAP) for patients with severe CAP in ICU, with capability of rapid adaptation to new public health threats as demonstrated. In a response to COVID-19 the platform was (within 2 months) adapted with new COVID-19 treatment domains and enrolment of non-ICU patients, and the number active sites rapidly increased in 213 sites (June 4th) with 1084 patients enrolled (567 with COVID-19).
Supportive to the clinical studies are work packages LAB (for laboratory support), DATA (for datamanagement and innovative epidemiological and statistical research), TRAIN (for training) and PREP (for improving responsiveness to new public health threats).
ECRAID-Base, therefore, establishes a pan-European clinical research network to increase efficiency for testing and developing new diagnostic, preventive and/or therapeutic strategies and therapies and improving responsiveness to new public health thretbd

Convocatoria de propuestas

H2020-SC1-BHC-2018-2020

Consulte otros proyectos de esta convocatoria

Convocatoria de subcontratación

H2020-SC1-2020-Single-Stage-RTD

Régimen de financiación

RIA - Research and Innovation action

Coordinador

STICHTING EUROPEAN CLINICAL RESEARCH ALLIANCE ON INFECTIOUS DISEASES
Aportación neta de la UEn
€ 4 376 078,75
Dirección
ARCHIMEDESLAAN 6
3584 BA Utrecht
Países Bajos

Ver en el mapa

Pyme

Organización definida por ella misma como pequeña y mediana empresa (pyme) en el momento de la firma del acuerdo de subvención.

Región
West-Nederland Utrecht Utrecht
Tipo de actividad
Other
Enlaces
Coste total
€ 4 376 078,75

Participantes (21)